Concert Pharmaceuticals
2006
FOUNDED
PUBLIC
STATUS
71-80
EMPLOYEES
CNCE
STOCK SYMBOL
$5.88
SHARE PRICE
(As of Friday Closing)
Description
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 99 Hayden Avenue
- Suite 500
- Lexington, MA 02421
- United States
+1 (781) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Concert Pharmaceuticals’s full profile, request a free trial.
Concert Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $5.36 - $17.83 | $140M | $5.86 | -$3.34 | 210K | 23.8M |
Concert Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 143,249 | 116,427 | 382,015 | 121,210 |
| Revenue | 1,078 | 10,505 | 143,891 | 174 |
| EBITDA | (77,110) | (54,464) | 97,162 | (49,827) |
| Net Income | (78,730) | (56,024) | 95,639 | (50,720) |
| Total Assets | 166,601 | 192,547 | 211,736 | 100,395 |
| Total Debt | 16,579 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Concert Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookConcert Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookConcert Pharmaceuticals Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cortexyme | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
| 0 000000000000 | Venture Capital-Backed | Salt Lake City, UT | 000.00 | 00000 00000 | 000.00 | |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 00000000000 | |
| 00000 | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
| 0000000 | Venture Capital-Backed | Singapore, Singapore | 00 | 00000 | 0000000000 0 | 00000 |
Concert Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookConcert Pharmaceuticals Executive Team (7)
2 Former Executives
You’re viewing 5 of 7 executives. Get the full list »Concert Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Christi van Heek | Concert Pharmaceuticals | Board Member | 000 0000 | |
| Peter Hutt | Self | Board Member | 000 0000 | |
| Richard Aldrich | Self | Chairman & Founder | 000 0000 | |
| Ronald Barrett Ph.D | Self | Board Member | 000 0000 | |
| Wendell Wierenga Ph.D | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 12 board members. Get the full list »